Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the ...

The FDA announced on Thursday a proposed order to remove oral phenylephrine as an active ingredient in over-the-counter (OTC) ...

A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Cholinergic drugs (acetylcholine and methacholine ... Tiotropium, the first-choice long-acting bronchodilator in COPD, has been studied in severe asthmatics and in COPD patients with a history ...

The drug was administered twice-daily using a ... phosphodiesterase 3 and 4 (PDE3 and PDE4), and is thought to combine bronchodilator and anti-inflammatory properties in one compound.

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

Verona filed for approval of ensifentrine last year on the strength of clinical data showing significant improvements in lung function with the drug in COPD patients, as well as a reduction in ...

Do cough, cold or other respiratory issues disrupt your sleep in the rising air pollution? Explore the best nebulizer ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...